Geocann expands cannabis scientific research leadership with first human β-caryophyllene (BCP) published study demonstrating the safety and performance of novel formulation
VESIsorb drug delivery technology-based formulation dramatically improves all measured pharmacokinetic (PK) parameters of BCP compared to BCP neat oil.
Geocann is proud to announce that the peer-reviewed journal, Molecules, has published the results of a randomized, double-blind, cross-over design, single oral dose study [100 mg β-caryophyllene (BCP)] in 24 healthy subjects (12 men/12 women) performed under fasted conditions. The study evaluated the relative bioavailability of BCP formulated with VESIsorb to that of the same BCP neat oil. Overall, the VESIsorb formulation showed dramatic improvements for all measured pharmacokinetic parameters, including a 360% increase in maximal plasma BCP concentration (Cmax), a 220% increase in area under the curve (AUC), and a 215% faster time to peak absorption (Tmax).
BCP is a natural bicyclic sesquiterpene and a common constituent of the essential oils of numerous food plants, such as hemp (Cannabis sativa L), and is thought to interact with the endocannabinoid system by binding selectively to cannabinoid receptors type 2 (CB2).
“While decades of preclinical research have investigated the potential therapeutic benefits of BCP – such as analgesic, anti-inflammatory, and anti-depressive – this trailblazing study provides the scientific data demonstrating a VESIsorb technology-based BCP API reaches therapeutic plasma levels faster and more efficiently,” Dr. Anthony Petraglia, Chief Medical Officer of Geocann, said. “Simply put, improved bioavailability with VESIsorb directly translates to safely delivering higher BCP plasma levels with a much lower dose while maximizing therapeutic benefits.”
In addition to the superior PK results of the BCP VESIsorb formulation, there are significant findings that highlight the scientific and medical contributions from this new study.
- This is the first published study to demonstrate safe and well-tolerated BCP doses as high as 100 mg, which is a 10x increase compared to the natural daily human exposure.
- This is the first published study to demonstrate that BCP has poor bioavailability in humans.
- This is the first published study to reveal there is no significant difference between men and women for both investigated formulations and all investigated PK endpoints.
This study provides further evidence ofVESIsorb as the leading drug delivery system technology todramatically improve the bioavailability of poorly absorbed ingredients – suchas cannabinoids, terpenes, coenzyme Q10, QH Ubiquinol, vitamin D, and omega-3essential fatty acids, among others.
Geocann has the exclusive global rights to the clinically proven VESIsorbdrug delivery technology for cannabinoids, terpenes, and flavonoidformulations. The company is strategically partnering with leading medical,pharmaceutical, and wellness brands that share a commitment to superior productsafety, quality, and performance, and they have already commercialized BCP VESIsoormulations with category leaders like Nestlé Health Science, Theralogix, and Cronos.
“As our unmatched IP portfolio and body of supporting scientific evidence continues to expand, we are grateful for the peerless reputation the company is receiving in the global marketplace,” said Jesse Lopez, CEO and Founder of Geocann. “Most importantly, Geocann is proud of the support we provide to the leading brands we serve, and nothing gives a brand a better advantage than a peer-reviewed published study showing their products work better than competitive offerings.”